by New research suggests that targeted therapy can significantly prolong the lives of patients diagnosed with cancers of unknown primary origin (CUP). According to a recent report from Reuters Health, a study presented at the European Society for Medical Oncology (ESMO) Congress revealed that certain targeted therapies have shown promising results in treating CUP, which accounts for approximately 3-5% of all cancer diagnoses.
The study, led by Dr. Daniela Boffetta from the Icahn School of Medicine at Mount Sinai in New York, analyzed data from over 1,500 patients with CUP who received targeted therapy between 2010 and 2018. The researchers found that those who received targeted therapy had a median survival of 11 months, compared to 7 months for those who did not receive the treatment.
Targeted therapy, also known as molecular targeted therapy, is a type of cancer treatment that uses drugs or other substances to identify and attack specific proteins or genes in cancer cells. This approach can be particularly effective for CUP, as the primary tumor is often not present or difficult to identify, making traditional treatments less effective.
Targeted therapy, also known as molecular targeted therapy, is a type of cancer treatment that uses drugs or other substances to identify and attack specific proteins or genes in cancer cells. This approach can be particularly effective for CUP, as the primary tumor is often not present or difficult to identify, making traditional treatments less effective.
Dr. Boffetta emphasized the importance of early diagnosis and treatment for CUP patients, as well as the need for more research into the effectiveness of targeted therapy for this patient population. “Our study shows that targeted therapy can significantly improve survival for some patients with CUP,” she said. “However, we need to identify which patients are most likely to benefit and develop new strategies to diagnose and treat CUP earlier.”
The researchers noted that more studies are needed to confirm these findings and to identify the most effective targeted therapies for different subtypes of CUP. They also called for increased funding for research into the causes and treatments of CUP, as well as the development of new diagnostic tools to help identify the primary tumor site.
The study provides encouraging evidence that targeted therapy can extend survival for patients with CUP, a group of cancers that are often difficult to diagnose and treat. Further research is needed to identify which patients are most likely to benefit from this approach and to develop new diagnostic and treatment strategies for CUP.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
